Industry
Biotechnology
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.
Loading...
Open
0.28
Mkt cap
6M
Volume
671K
High
0.32
P/E Ratio
-0.17
52-wk high
2.19
Low
0.27
Div yield
N/A
52-wk low
0.18
Portfolio Pulse from Benzinga Insights
October 25, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Insights
October 25, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Insights
October 25, 2024 | 12:07 pm
Portfolio Pulse from Avi Kapoor
October 25, 2024 | 10:05 am
Portfolio Pulse from Benzinga Insights
October 24, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
October 11, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
October 07, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
October 01, 2024 | 3:19 pm
Portfolio Pulse from Benzinga Newsdesk
October 01, 2024 | 10:37 am
Portfolio Pulse from Benzinga Insights
September 30, 2024 | 4:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.